NurExone Logo Rebrand-large.png
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
September 26, 2024 16:03 ET | NurExone Biologic Inc
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
NurExone Logo Rebrand-large.png
NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences
September 12, 2024 16:04 ET | NurExone Biologic Inc
NurExone Biologic Enhances Visibility in Pharmaceutical Industry with Technological Presentations at Major Global Events
Homing Post Injury - ExoPTEN
NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
September 06, 2024 16:03 ET | NurExone Biologic Inc
NurExone demonstrates a longer timeframe of ExoPTEN treatment can be effectively administered post Spinal-Cord Injury
NurExone Logo Rebrand-large.png
NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 28, 2024 08:34 ET | NurExone Biologic Inc
NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
NurExone Logo Rebrand-large.png
NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences
August 23, 2024 16:03 ET | NurExone Biologic Inc
NurExone Biologic to present its innovative ExoPTEN therapy at key September conferences in Boston and New York, showcasing its leadership in regenerative
2024_Process Robustness
NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process
August 15, 2024 16:03 ET | NurExone Biologic Inc
NurExone’s reliable production from diverse biological sources allows NurExone to optimize exosome production with consistency and efficiency
Figure 1
NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
August 09, 2024 16:04 ET | NurExone Biologic Inc
NurExone announces promising new data for its ExoPTEN nanodrug, highlighting progress towards commercial-grade manufacturing
Figure 1
NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer
August 01, 2024 16:04 ET | NurExone Biologic Inc
NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer
NurExone Logo Rebrand-large.png
NurExone Announces Further Expansion of ExoPTEN Patent Coverage
July 29, 2024 16:04 ET | NurExone Biologic Inc
NurExone Announces Further Expansion of ExoPTEN Patent Coverage in Israel
Electroretinogram (ERG) measurements
Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma
July 17, 2024 16:14 ET | NurExone Biologic Inc
TORONTO and HAIFA, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...